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Background:	Introduction	
	
The	average	person	has	up	to	15%	lifetime	risk	for	developing	depression13.	Major	depressive	disorder	symptoms	
can	include	a	depressed	mood,	such	as	feeling	sad	or	having	more	anger	than	normal,	changes	in	appetite,	loss	of	
interest	in	activities	or	hobbies,	psychomotor	agitation	or	retardation,	loss	of	energy,	feelings	of	worthlessness	or	
guilt,	decreased	ability	to	think	or	concentrate,	sleep	disturbance,	an/or	having	suicidal	thoughts.	To	make	the	
diagnosis	of	major	depressive	disorder,	according	to	the	DSM-V,	Diagnostic	and	Statistical	Manual	of	Mental	
disorders,	a	person	must	have	at	least	5	or	more	of	these	9	symptoms	during	a	continuous	two-week	period	which	
causes	significant	impairment	in	functioning1.	Depression	is	treated	in	a	variety	of	ways	including	medications	and	
psychotherapy	either	as	monotherapy	or	in	tandem.	When	a	patient	has	failed	2	or	more	medication	treatments	
they	are	considered	treatment	resistant	or	as	having	refractory	depression.	Treatment	resistant	depression	or	
refractory	depression	has	several	standard	therapies,	which	include	combination	pharmacotherapy,	
electroconvulsive	therapy,	or	ECT,	transcranial	magnetic	stimulation,	or	TMS,	vagal	nerves	stimulation	and	deep	
brain	stimulation.	Current	research	does	support	that	a	novel	therapy,	such	as	ketamine	infusions,	may	help	
patients	in	the	short-term	with	their	depressive	symptoms,	including	suicidal	ideation.	The	focus	of	this	paper	is	to	
review	the	clinical	trials	involving	ketamine	use	in	refractory	depression	for	the	alleviation	of	depressive	
symptoms,	including	suicidal	ideation,	and	to	examine	the	benefits,	limitations,	and	future	potential	for	ketamine	
as	a	treatment	for	refractory	depression.		
	
Epidemiology:		
	
Depression	varies	across	sex,	socioeconomic	status,	age	and	race.	Many	people	who	seek	treatment	for	depression	
have	a	chronic	relapsing-remitting	course	of	the	illness6.		The	prevalence	of	depression	usually	increases	during	the	
teenage	years	throughout	early	to	mid	20s,	with	an	average	age	of	onset	in	the	mid	20s6.	Adults	over	the	age	of	60	
have	a	lower	rate	of	depression	than	other	age	demographics13.	Females	have	a	greater	prevalence	for	depression	
in	all	age	groups	studied	by	the	Centers	for	Disease	Control	and	Prevention	(CDC)13.	Hispanic	and	Non-Hispanic	
black	persons	have	a	higher	rate	of	mild	to	moderate	depressive	symptoms	than	Non-Hispanic	white	persons,	who	
were	more	likely	to	have	no	depressive	symptoms13.	Socioeconomic	levels	have	been	shown	to	have	an	effect	on	
levels	of	depression,	with	people	below	the	poverty	line	being	twice	as	likely	to	have	depression13.	In	studying	
refractory	depression	in	primary	care	settings	across	Canada	there	was	no	significant	prevalence	difference	in	men	
versus	women14.	Patients	with	refractory	depression	were	more	likely	to	have	longer	depressive	episodes,	with	
higher	rates	of	comorbid	illnesses,	such	as	cardiac	disease	or	anxiety	or	personality	disorders14.	In	patients	with	RD	
(refractory	depression)	there	is	a	higher	chance	of	polypharmacy	with	increased	side	effects	and	decreased	ability	
to	work,	indicating	that	with	RD	a	patient’s	life	may	be	more	severely	affected	long-term14.		
	
Pathophysiology:		
	
Currently,	the	cause	of	depression	is	not	fully	understood.	There	are	a	variety	of	diverse	risk	factors	that	are	
positively	correlated	with	the	diagnosis	of	depression	and	may	act	at	different	stages	of	development.	Variables	
may	include	genetics	and	environmental	factors,	psychosocial	adversity,	anxiety	disorders,	and	substance	misuse5.	
Studies	have	shown	through	familial,	twin	and	adoptions	that	there	is	a	strong	link	in	the	genetic	aspect	to	
depression,	with	up	to	40%	directly	correlated	to	genetic	factors3.	The	remaining	variance	may	be	associated	with	
childhood	traumatic	events	and	lifetime	adversity3.	Other	theories	focus	on	the	hormonal	aspects	of	depression,	
such	as	altered	hypothalamic-pituitary	axis	activity,	monoamine	deficiency,	reduced	gamma-amino-butyric	
acid	(GABA)	activity,	dysfunction	of	the	glutamate	system	or	impaired	circadian	rhythms3.	For	all	of	the	hypotheses	
surrounding	depression,	there	are	both	strengths	and	limitations.	Many	of	the	limitations	revolve	around	not	
having	specific	genes	or	evidence	in	humans.	The	lack	of	a	unified	theory	for	the	pathophysiology	of	depression	is	
indicative	of	a	very	complex	and	incompletely	understood	disease. 
	
Diagnosing	Depression:		
	
When	diagnosing	depression,	providers	are	guided	by	the	DSM-V	and	physiological	instruments,	such	as	the	PHQ9,	
which	are	increasingly	utilized	in	both	the	diagnosis	and	management	of	depressive	disorders.	The	criteria	are	
based	on	the	clinical	findings	or	what	the	patient	is	feeling	or	another	person	is	observing	so	it	is	important	to	get	
an	accurate	history	and	physical	examination.	Providers	must	be	thorough	in	order	to	make	the	diagnosis	of	
depression	taking	into	account	the	patient’s	current	life	events	and	medical	and	mental	comorbidities.	Depression	
is	often	missed	in	the	primary	care	setting.	There	are	several	tools	available	that	providers	may	use	to	assess	for	
depression	before	a	clinical	visit	begins,	but	a	thorough	patient	interview	is	necessary	as	well.	A	provider	must	look	
at	the	patient’s	symptoms	to	assess	for	depression:	depressed	mood,	loss	of	interest	or	pleasure,	appetite	or	
weight	changes,	trouble	sleeping	or	sleeping	too	much,	psychomotor	agitation	or	retardation,	loss	of	energy	or	
excessive	fatigue,	guilt	or	feeling	worthless,	decreased	ability	to	concentrate,	and	suicidal	thoughts	or	recurrent	
thoughts	of	death.	Assessing	for	suicidal	risk	is	crucial	during	the	interview	and	may	determine	whether	a	patient	
needs	inpatient	or	outpatient	treatment.		
	
Table	1.	DSM-V	criteria	for	Major	Depressive	Disorder.		
Five	or	more	of	the	following	symptoms,	which	represents	a	change	from	baseline	and	have	been	presents	for	at	least	a	
2-week	period;	must	include	either	depressed	mood	or	loss	of	interest	or	pleasure.		
1. 	 Depressed	mood	
2. 	 Loss	of	interest	or	pleasure	
3. 	 Weight	change:	unintentional	weight	gain	or	weight	loss	or	change	in	appetite	
4. 		 Insomnia	or	hypersomnia	
5. 	 Psychomotor	agitation	or	retardation	
6. 	 Fatigue	or	loss	of	energy	
7. 	 Feelings	of	worthlessness	or	inappropriate	guilt	
8. 	 Decreased	ability	to	think	or	concentrate	
9. 	 Recurrent	thoughts	of	death,	recurrent	suicidal	ideation	with	or	without	a	specific	plan	
Symptoms	cause	a	clinically	significant	impairment	or	distress	in	everyday	functioning	
Symptoms	or	depressive	episode	not	due	to	another	medical	condition	or	substance	use	
The	disorder	is	not	better	explained	by	another	mental	health	disorder.		
	
Differential	Diagnosis:		
	
Distinguishing	unipolar	depression,	or	depression	without	mania,	from	other	disorders	that	manifest	similarly	
helps	guide	and	focus	the	treatment.	Depression	may	look	similar	to	other	psychiatric	disorders	or	may	be	caused	
by	a	medical	condition.	A	generalized	workup	is	necessary	to	help	narrow	down	the	differential.	When	a	patient	
presents	with	new	onset	depressive	symptoms	a	thorough	history,	physical	examination	and	lab	work	is	required.	
Taking	into	context	the	DSM-V	is	crucial	to	help	differentiate	depression	from	other	psychiatric	disorders	including	
but	not	limited	to:	Schizophrenia,	Bipolar	disorder,	anxiety	or	ADHD,	Depressive	symptoms	are	not	limited	to	
mental	illness.	Many	medical	conditions	can	mimic	depression	and	cloud	a	practitioner's	clinical	picture.	A	
thorough	physical	examination	and	blood	work	can	help	rule	out	depression	due	to	a	medical	condition.	Examples	
of	medical	conditions	that	may	cause	depressive	symptoms	can	include	the	following:	substance	induced	mood	
disorder,	hypothyroidism,	hypoglycemia,	and	chronic	fatigue	syndrome.		
	
Treatment:	
	
First-line	treatment	for	depression	may	involve	psychotherapy,	most	specifically	Cognitive	behavioral	therapy,	
medication,	or	a	combination	of	psychotherapy	and	medication.	This	paper	will	focus	on	the	pharmacological	
approaches	to	depression.	Psychotherapy	or	medication	is	considered	first	line	in	treating	depression	and	
psychotherapy	may	be	used	as	monotherapy	or	in	combination	with	medication.	The	first	line	medication	
therapies	include:	selective	serotonin	reuptake	inhibitors	(SSRIs),	serotonin	and	norepinephrine	reuptake	inhibitors	
(SNRIs),	and	the	norepinephrine-dopamine	reuptake	inhibitor	(NDRI)7.	Treatment	is	chosen	based	on	a	continuing	
assessment	of	the	patient’s	symptoms	and	side	effects	and	any	previous	drug	trials	the	patient	has	had.	Older	drug	
classes,	such	as	tricyclic	antidepressants	(TCAs),	monoamine	oxidase	inhibitors	(MAOIs),	or	
	antipsychotics	are	generally	reserved	for	patients	that	do	not	have	a	satisfactory	response	to	first-line	
antidepressants.	Patients	are	usually	started	at	the	minimum	therapeutic	dose	and	titrated	upward	over	the	
course	of	several	weeks,	depending	on	the	clinician’s	judgement;	a	second	drug	may	be	added	if	the	patient	is	
having	inadequate	symptomatic	relief	with	one	medication.	Patients	are	told	that	symptomatic	relief	may	occur	
within	a	few	weeks	or	a	number	of	months.		
	
A	patient	who	does	not	respond	to	two	or	more	adequate	trials	of	antidepressant	(with	adequacy	determined	by	
medication	duration	and	dose)	is	considered	treatment	resistant.	Patients	who	experience	refractory	depression	
have	a	lower	quality	of	life	in	addition	to	more	medical	visits	and	higher	financial	burden	on	the	healthcare	system.	
The	excess	burden	and	lower	quality	of	life	may	also	contribute	to	increased	anxiety,	depression	and	other	
comorbid	disorders11.		
	
Current	standard	of	care	for	patients	who	are	resistant	to	treatment	includes	combination	pharmacotherapy	in	
which	the	provider	works	to	optimize	the	medication	the	patient	is	on	and	augments	current	treatment	by	adding	
additional	medication.	
	
Research	has	been	working	towards	increasing	treatment	options	for	patients	who	fail	even	the	standardized	
treatment	options	for	resistant	depression,	and	one	of	the	pathways	to	achieve	this	is	through	non-monoaminergic	
approaches,	such	as	the	N-methyl-D-aspartate	(NMDA)	receptor	antagonists,	like	ketamine.		
	
Ketamine:		
	
Ketamine	was	initially	introduced	as	an	anesthetic,	but	throughout	the	years	it	has	been	demonstrating	effects	in	a	
variety	of	different	roles,	including	analgesia	and	therapy	for	treatment-resistant,	or	refractory,	depression.	
Ketamine	is	a	structural	analog	for	Phencyclidine,	a	known	hallucinogen,	and	was	discovered	in	19629.	Ketamine	
was	shown	to	produce	quick	acting	analgesia	of	short	effect	and	minimal	side	effects	and	lack	of	severe	delirium	
that	its	parent	compound,	phencyclidine,	produced9.		
	
Ketamine	is	an	arylcycloakylamine	derivative	that	exists	in	S(+)	and	R(-)	isomers	and	is	commonly	used	in	medicine	
as	a	racemic	mixture	of	both9.	Ketamine	works	as	a	NMDA	antagonist,	binding	to	the	receptors	and	causing	an	
anesthetic	effect.	Ketamine	is	available	in	several	different	forms	including	intravenous	(IV),	intramuscular	(IM),	
oral,	nasal,	rectal,	subcutaneous	(SQ),	and	epidural	administration.	IV	ketamine	has	the	highest	bioavailability	at	
100%,	with	IM	following	at	93%9.	Ketamine	has	a	quick	onset	of	action	due	to	its	short	half-	life	of	10-15	minutes	
and	lipid	solubility9.	Ketamine	has	generally	been	dosed	up	to	1mg/kg,	though	lower	doses	may	achieve	sedation.		
	
Ketamine	is	most	commonly	used	in	anesthesia	and	sedation,	but	in	recent	years	its	psychiatric	uses	are	being	
explored	in	refractory	depression.	This	paper	will	explore	the	role	of	ketamine	in	the	improvement	of	symptoms	in	
refractory	depression	including	suicidal	ideation	along	with	the	potential	benefits	and	limitations	of	use.		
	
Methods:		
	
Initial	search	of	UpToDate,	then	PubMed	with	the	following	search	terms:	‘ketamine	and	depressive	disorders’,	
‘ketamine	and	depression,’	and	‘ketamine	and	refractory	depression’.	Uptodate	search	was	used	to	supplement	
background	information	and	provide	framework	and	structure	for	searching	in	Pubmed.		
	
A	literature	search	was	performed	using	Pubmed	with	the	follow	terms:		ketamine;	depression;	depressive	
disorder.	Included	articles	that	were	clinical	trials,	written	in	English,	published	within	the	last	5	years.	Of	the	
original	539	articles	the	filtered	search	yielded	57	articles.		
	
The	Cochrane	Bias	Tool	was	utilized	in	order	evaluate	articles	by	analyzing	selection,	performance,	detection,	
attrition,	and	reporting	bias.	The	criteria	that	were	analyzed	included:	Drug	administration,	dosage	and	treatment	
duration,	blinding	versus	non-blinded	studies,	sample	sizes,	placebo	versus	active	drugs,	remission	rates,	side	
effects,	follow-up,	and	outcomes	of	the	study.	See	table	below	for	further	details.			
	
Results:		
	
Murrough	et	al.	(2015)	demonstrated	that	after	a	single	dose	of	ketamine	suicidal	ideation	was	decreased	in	the	
sample	group	at	48	hours12.	This	trial	used	a	single	dose	of	ketamine	and	then	the	patient’s	symptoms	were	
assessed	at	24,	48,	and	72	hours	and	7	days.	Patients’	symptoms	were	significantly	decreased	in	the	Ketamine	
group	at	48	hours	(8.8+/-8.3	and	15.3+/-10.9	F1,21=4.45,	p=0.047).	The	most	common	observed	side	effects	of	
ketamine	were	headache,	dizziness,	anxiety,	poor	concentration	and	coordination,	most	of	which	resolved	by	the	
end	of	infusion.	This	trial	was	limited	in	the	fact	that	there	was	no	long-term	follow	up	and	it	only	looked	at	
reduction	of	suicidal	ideation	as	the	outcome.	The	same	size	was	small	at	24	participants.		
	
Singh	et	al.	(2016)	was	a	clinical	trial	consisting	of	67	participants	(45	women)	who	were	administered	ketamine	2	
or	3	times	weekly	or	IV	placebo15.	The	outcomes	were	measured	using	Montgomery	Asberg	Depression	Rating	
scale	(MADRS).	Both	ketamine	groups	had	improvement	in	their	MADRS	score	from	day	1	to	15	(twice	weekly	=	-
18.4	(SD	12)	and	thrice	weekly	=	-17.7	(SD	7.3)	compared	to	placebo:	-5.7	(SD	10.2)	and	-3.1	(SD	5.7).	The	study	
also	looked	at	the	secondary	outcome	of	baseline	MADRS	score	to	day	29	and	found	that	the	ketamine	groups	
showed	improvement	over	a	longer	period	of	time	compared	to	the	placebo	(twice	weekly	-21.2	(SD	12.9)	and	
thrice	weekly	-21.2	(SD	11.2)	versus	placebo	(-4.0	(SD	.1)	and	-3.6	(SD	6.6)).	The	study	was	limited	because	there	
was	no	long-term	follow	up	beyond	6	weeks.	Also,	because	patients	did	have	side	effects	while	taking	ketamine	
infusions	(headache,	anxiety,	dissociation,	nausea,	and	dizziness)	there	is	the	possibility	of	unblinding.	Overall,	this	
study	did	demonstrate	that	improvement	in	patients’	subjective	symptoms	of	depression	is	possible	with	ketamine	
even	at	less	frequent	dosing,	such	as	twice	weekly	vs	thrice	weekly.		
	
Losifescu	et	al.	(2013)	was	a	clinical	trial	of	72	participants	who	had	failed	3	or	more	trials	of	antidepressants	and	
had	a	diagnosis	of	major	depressive	disorder4.	The	participants	were	randomized	into	control	(midazolam)	or	
active	(ketamine)	groups.	Participants	received	1	dose	over	40	minutes.	Severity	of	depression	was	assessed	
continuously	for	the	first	24	hours	and	then	again	at	48	and	72	hours	and	7	days	utilizing	the	MADRS	scoring	
system.	The	mean	score	was	lower	in	the	ketamine	group	by	7.95	points	(CI	3.20	to	12.71).	Both	groups	showed	
worsening	of	MADRS	score	each	day	after	infusion.	(B=0.0004;	95%	CI	0.00009	to	0.00062).	The	time	to	relapse	
was	measured	between	4	midazolam	responders	and	21	ketamine	responders,	which	showed	a	greater	portion	of	
patients	without	relapse	in	the	ketamine	responder	group.	The	single	infusion	administration	of	ketamine	was	a	
limitation	for	the	study,	as	the	effects	of	more	frequent	dosing	and	remission	rates	at	greater	time	intervals	from	
the	infusion	are	unknown.		This	study	does	support	that	even	with	a	single	infusion	or	dose	of	ketamine	there	is	
reduction	in	the	severity	of	depression	measured	subjectively	by	the	participants.		
	
Lapidus	et	al.	(2014)	demonstrated	a	novel	use	of	intranasal	ketamine.	The	sample	size	was	18	and	randomized	
into	control	(saline	solution)	and	intranasal	ketamine8.	Participants	were	assessed	at	40,	120,	240	minutes	and	48,	
72	hours	and	7	days.	Symptoms	improved	after	24	hours	in	the	treatment	group	compared	to	the	placebo	(T=	4.39,	
p	<0.001)	with	a	mean	difference	in	MADRS	score	of	7.6+/-	3.7	(95%	CI,	3.9-11.3).	The	greatest	effect	was	seen	at	
24	hours	with	no	significant	difference	seen	between	both	groups	at	7	days.	Limitations	for	this	study	include	the	
small	sample	size,	possibility	of	unblinding	with	side	effects	from	ketamine	(dissociation,	poor	memory,	weakness	
and	fatigue),	short	time	frame	of	study,	and	ketamine	use	in	conjunction	with	the	patient’s	current	therapy	rather	
than	as	a	monotherapy.		The	study	did	show	that	there	was	a	favorable	response	when	using	MADRS	scoring	and	
there	were	minimal	side	effects.	This	introduced	intranasal	ketamine	versus	IV	infusion,	which	may	be	significant	
because	intranasal	may	be	more	easily	administered	to	patients	than	IV.		
	
Burger	et	al.	(2016)	looked	at	acute	depression	and	suicidality	in	a	military	emergency	department	setting.	A	
sample	size	of	10	participants	with	depression	measured	using	the	Beck	Suicidality	Scale	(BSS)	was	randomized	into	
a	ketamine	group	and	a	placebo	(normal	saline)	group2.	Patients	were	assessed	before	drug	administration	and	40,	
80,	120,	and	240	minutes	after	administration.	BSS	showed	significant	linear	effects	of	time	(p	<0.05),	but	not	
group	(p>0.05).	There	was	significant	linear	time	x	group	interaction	(p<0.05)	over	the	4	hour	ED	observation	
period.	BSS	at	follow-up	or	discharge	was	not	significant	between	groups.	BHS,	Beck	Hopelessness	score,	showed	
neither	significant	effect	of	time	or	group,	but	the	time	x	group	intervention	was	significant.	BHS	scores	were	
significantly	different	at	discharge,	but	not	at	follow-up.	Limitations	include	a	small	sample	size	and	lack	of	data	on	
long-term	effects	on	remission	and	side	effects	of	ketamine	use.	The	study	was	considered	a	failed	trial	due	to	
record-keeping	trouble	and	was	terminated	early.	There	was	sparse	data	on	the	results	and	statistical	analysis.	It	
did	indicate	that	there	was	potential	for	ketamine	in	an	acute	setting	with	a	reported	67%	of	patients	showing	a	
decrease	in	SI	and	depression	symptoms.		
	
Loo	et	al.	(2016)	compared	dose	titration	with	IV,	IM,	and	SQ	routes	for	ketamine	in	depression10.	The	sample	size	
was	15	participants	who	received	either	ketamine	or	midazolam.	Ketamine	was	administered	by	IV,	IM,	or	SQ	
routes	and	dose	titrated	up	at	0.1	mg/kg	to	0.4	mg/kg.	MADRS	was	measured	on	day	1	of	ketamine	treatment	and	
at	4	hours	and	2,	4,	and	7	days	after	each	treatment.	12	out	of	15	patients	met	the	criteria	for	both	response	and	
remission	at	some	point	during	the	trial,	with	an	overall	acute	response/remission	rate	of	75%	(IV),	60%	(IM)	and	
100%	(SQ).	Mean	time	to	relapse	was	23.2	days.	There	was	no	difference	in	MADRS	scores	between	routes	of	
administration.	Overall,	there	was	short-term	improvement	in	both	0.2mg/kg	and	0.1mg/kg	dosing	versus	placebo,	
although	there	was	no	linear	trend.	Placebo	and	ketamine	groups	showed	no	statistical	difference	at	day	7	post-
treatment.	Side	effects	for	ketamine	were	observed	at	higher	doses.	The	limitations	in	this	trial	include	the	small	
sample	size,	placebo	vs	treatment	group	was	by	sequential	cohorts	rather	than	randomized,	dosing	was	titrated	
rather	than	randomized,	and	ketamine	was	not	studied	as	a	monotherapy.	This	study	did	reveal	that	dosing	
response	was	based	on	the	individual.	Different	individuals	responded	differently	to	different	doses,	indicating	that	
ketamine	may	need	to	be	dosed	on	an	individual	basis.	This	was	the	first	trial	reviewed	which	included	SQ,	IM,	and	
IV	administration	of	ketamine.		
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dizziness	on	standing,	
anxiety,	poor	
concentration,	poor	
coordination	and	
restlessness	
Assessed	at	24,	48,	72	hours	
and	7	days	post-treatment.	
24	hours	after	treatment	
there	was	no	significant	
difference	in	baseline	SI	
between	groups	(10.8+/-	8.5	
and	14	+/-	10.2	for	ketamine	
and	midazolam)	
At	48	hours	decrease	in	
baseline	suicidal	ideation	
compared	to	the	control	
group	(8.8+/-8.3	and	15.3+/-
10.9	F1,21=4.45,	p=0.047)		
No	statistical	difference	
between	groups	at	72	hours	
and	7	days	
	
Not	available	 Single	dose	of	
ketamine	with	no	
long	term	follow	
up.		
Only	looked	at	
reduction	of	SI	for	
outcomes	
Small	sample	size		
No	data	on	effects	
of	Ketamine	as	
monotherapy	
	
Demonstrated	
tolerability	to	
ketamine	and	
supports	the	data	
that	ketamine	has	
potential	for	rapid	
decrease	in	SI.	More	
studies	needed	to	
study	the	long-term	
effects	of	ketamine.		
A	double-blind,	
randomized,	
placebo-
controlled,	dose-
frequency	study	
of	Intravenous	
ketamine	in	
patients	with	
Treatment-
resistant	
depression	
Singh	et	al.,	
201615	
Sample	size:	67	(45	
women)	ages	18	-64	
years	old.		
Patients	randomized	in	
1	of	4	treatment	
groups:	IV	ketamine	
(0.5mg/kg);	
administrated	2	or	3	
times	weekly	or	IV	
placebo	(0.9%	sodium	
chloride);	administered	
2	or	3	times	weekly.		
Depression	measured	
using	MADRS	=	
Montgomery-Asberg	
Most	common	
treatment	adverse	
events	were	headache,	
anxiety,	dissociation,	
nausea,	and	dizziness	
(most	commonly	on	day	
of	dosing	and	resolved	
within	2	hours)	
	No	deaths	were	
reported,	but	two	
serious	emergent	
adverse	events	
occurred	(unrelated	to	
ketamine);	anxiety	(life	
related)	and	suicide	
Primary	Outcomes:	mean	
baseline	in	MADRS	score	
from	day	1	to	15	improved	in	
both	ketamine	frequency	
groups	(twice	weekly	=	-18.4	
(SD	12)	and	thrice	weekly	=	-
17.7	(SD	7.3)	compared	to	
placebo:	-5.7	(SD	10.2)	and	-
3.1	(SD	5.7)	
Secondary	outcomes:	MADRS	
mean	score	improved	from	
baseline	to	day	29	in	
ketamine	groups	(twice	
weekly	-21.2	(SD	12.9)	and	
thrice	weekly	-21.2	(SD	11.2))	
MADRS	
remission	at	day	
15:	Ketamine	
group	(twice	
weekly	N	=	6;	
37.5%.	thrice	
weekly	N	=	3;	
23.1%)	Placebo	
group	(twice	
weekly	N=	!;	
7.7%	and	thrice	
weekly	N=	0)	
Short	time	period	
assessed	of	4-6	
weeks		
	
No	long-term	
follow-up	
	
Possibility	for	un-
blinding	due	to	
adverse	events	
occurring	in	
treatment	group.		
Short-term	
improvement	in	
depression	is	
possible	with	
ketamine,	even	at	
less	frequent	dosing	
such	as	twice	
weekly.		
Further	studies	are	
needed	to	assess	
long-term	effects	of	
ketamine	and	rates	
of	remission	of	
treatment	resistant	
depression.		
Depression	Rating	Scale	 attempt	on	day	40	–	
more	than	40	weeks	
after	last	dose	
	
versus	placebo	(-4.0	(SD	.1)	
and	-3.6	(SD	6.6))	
Antidepressant	
Efficacy	of	
Ketamine	in	
treatment-
resistant	Major	
depression:	A	two	
site	Randomized	
controlled	trial	
Losifescu	et	al.,	
20134	
	
Sample	size:	72.	Ages	21	
to	80	years	old	with	
primary	diagnosis	of	
MDD	with	treatment	
failure	of	≥	3	
therapeutic	trials.		
	
Randomized	and	
received	either	single	
dose	IV	ketamine	HCL	
(0.5	mg/kg)	or	
midazolam	(0.045	
mg/kg)	infused	over	40	
minutes.		
Ketamine:	most	
common	AE	for	up	to	4	
hours	post-infusion	
were	dizziness,	blurred	
vision,	headache,	
nausea	or	vomiting,	dry	
mouth,	poor	
coordination,	poor	
concentration	and	
restlessness.	
Midazolam:	most	
common	AE	for	same	
time	frame	were	
general	malaise,	
dizziness,	headache,	
restlessness,	nausea	or	
vomiting,	dry	mouth,	
decreased	energy	and	
poor	coordination.		
8/47	ketamine	patients	
reported	dissociative	
symptoms;	which	
resolved	within	2	hours	
post-infusion	
	
Assessed	continuously	for	24	
hours,	then	at	48	hours,	72	
hours	and	7	days	post-
infusion.		
Primary	outcome:	reduction	
in	depression	severity	
assessed	by	MADRS	24	hours	
post-infusion.	Mean	score	
was	lower	in	ketamine	group	
by	7.95	points	(CI	3.20	to	
12.71).		
	
Both	groups	
showed	
worsening	of	
MADRS	score	
each	day	after	
infusion.	
(B=0.0004;	95%	
CI	0.00009	to	
0.00062).	The	
time	to	relapse	
was	measured	
between	4	
midazolam	
responders	and	
21	ketamine	
responders	
which	showed	a	
greater	portion	
of	patients	
without	relapse	
in	the	ketamine	
responder	group	
Single	dose	of	
ketamine	trial;	
unknown	what	
the	effect	would	
be	of	multiple	
dosing	over	the	
same	period	
studied.		
Unknown	long-
term	effects	of	
ketamine	
Study	supports	data	
that	ketamine	
causes	a	rapid	
response	with	only	
one	infusion	as	
monotherapy		
A	Randomized	
Controlled	Trial	of	
Intranasal	
ketamine	in	Major	
Depressive	
disorder	
Lapidus	et	al.,	
20148	
Sample	size	18.	Ages	
21-65	years	old.	Have	
failed	at	least	1	trial	of	
antidepressant	
medication.	Maintained	
standard	treatment	
during	trial.	
Randomized	into	
intranasal	ketamine	HCL	
50mg	and	placebo	
(0.9%	saline	solution)	
and	there	were	two	
treatment	days.		
	
Associated	with	small	
increases	in	psychosis	
and	dissociation,	
systolic	blood	pressure	
increases.		
Most	common	
emergent	AE	were	
feeling	strange	or	
unreal,	poor	memory	
and	weakness	or	fatigue	
–	most	of	these	
symptoms	resolved	
after	4	hours.		
Assessment	occurred	at	40,	
120,	240	minutes,	and	48,	72	
hours	and	7	days.	Symptoms	
improved	after	24	hours	in	
the	treatment	group	
compared	to	the	placebo	(T=	
4.39,	p	<0.001)	with	a	mean	
difference	in	MADRS	score	of	
7.6+/-	3.7	(95%	CI,	3.9-11.3)		
Greatest	effect	
was	seen	at	24	
hours.	MADRS	
scores	were	
similar	in	
ketamine	and	
control	group	at	
7	days.		
Did	not	assess	
Ketamine	as	
monotherapy		
Use	of	non-active	
placebo	with	no	
side	effects	could	
result	in	un-
blinding.		
Small	sample	size	
and	short	study	
time	frame	with	
no	long-term	
effects	measured.		
	
There	were	limited	
AE	and	patients	
who	received	
ketamine	had	a	
favorable	response	
when	evaluated	
using	MADRS.	
Introducing	
intranasal	ketamine	
as	form.	Need	to	
evaluate	long	term	
effects	and	with	
larger	sample	size	
A	Double-Blinded,	
Randomized,	
placebo-
controlled	sub-
dissociative	dose	
Ketamine	pilot	
study	in	the	
treatment	of	
Acute	Depression	
and	Suicidality	in	
a	Military	
Emergency	
Department	
setting	
Burger	et	al.,	
20162	
Sample	size	10.	Ages	18	
to	65	years	old.	
Depression	measured	
using	Beck	Suicidality	
Scale	(BSS),	BHS,	and	
Beck	Depression	
Inventory.	Randomized	
into	ketamine	active	
group	0.2	mg/kg	
infused	over	2	minutes	
and	placebo	group	with	
normal	saline.		
No	depersonalization,	
confusion,	
hallucinations	or	other	
adverse	symptoms	
associated	with	
ketamine	and	no	other	
adverse	effects	were	
noted	by	participants.			
Assessed	before	drug	
administration	and	40,	80,	
120,	and	240	minutes	after	
administration.	BSS	showed	
significant	linear	effects	of	
time	(p	<0.05),	but	not	group	
(p>0.05).	There	was	
significant	linear	time	x	group	
interaction	(p<0.05)	over	the	
4	hour	ED	observation	
period.	BSS	at	follow-up	or	
discharge	was	not	significant	
between	groups.	BHS	showed	
neither	significant	effect	of	
time	or	group,	but	the	time	x	
group	intervention	was	
significant.	BHS	scores	were	
significantly	different	at	
discharge,	but	not	at	follow-
up.		
	
Not	available		 Small	sample	size.		
No	long-term	
effects	on	
remission	
available	or	long-
term	effects	of	
ketamine	use.		
	
Sparse	data	on	
results	and	
statistical	analysis.		
	
Study	was	
terminated	early	
because	of	record-
keeping	trouble.		
Considered	failed	
trial	but	showed	
potential	for	
ketamine	for	acute	
depression	in	the	
ED	setting	with	67%	
of	patients	showing	
a	decrease	in	SI	and	
depression	
symptoms.		
Placebo-
controlled	pilot	
trial	testing	dose	
titration	and	
intravenous,	
intramuscular	and	
subcutaneous	
routes	for	
ketamine	in	
depression	
Loo	et	al.,	201610	
Sample	size:	15	patients	
diagnosed	as	treatment	
refractory	who	received	
ketamine	or	midazolam.	
Ketamine	was	
administered	by	IV,	IM,	
or	SQ	routes	and	dose	
titrated	up	at	0.1	mg/kg	
to	0.4	mg/kg.		
SE	were	observed	at	
higher	doses.	
Symptoms	included:	
depersonalization,	
derealization,	altered	
body	perception	and	
altered	time	perception.	
All	resolved	after	40	
minutes	post-infusion.	
Transient	elevation	
occurred	in	heart	rate,	
systolic	and	diastolic	
blood	pressure.		
Most	common	side	
effects	were	fatigue,	
light-headedness,	
dizziness,	blurred	vision	
and	emotional	lability.		
	
MADRS	was	measured	on	day	
1	of	ketamine	treatment	and	
at	4	hours,	2,	4,	and	7	days	
after	each	treatment.	12	out	
of	15	patients	met	the	
criteria	for	both	response	and	
remission	at	some	point	
during	the	trial.	With	an	
overall	acute	
response/remission	rate	of	
75%	(IV),	60%	(IM)	and	100%	
(SQ).	Mean	time	to	relapse	
was	23.2	days.	There	was	no	
difference	in	MADRS	scores	
between	routes	of	
administration.	Overall,	there	
was	short-term	improvement	
in	both	0.2mg/kg	and	
0.1mg/kg	dosing	versus	
placebo,	although	there	was	
no	linear	trend.			
Placebo	and	
ketamine	groups	
showed	no	
statistical	
difference	at	day	
7	post-
treatment.		
Small	sample	size		
	
Treatment	group	
was	by	sequential	
cohorts	rather	
than	randomized.		
	
Dosing	was	
titrated	versus	
randomized.		
	
Ketamine	was	not	
studied	as	
monotherapy			
Revealed	that	
dosing	response	
differed	among	
individuals,	
therefore	ketamine	
treatment	may	
need	to	be	dosed	
on	an	individual	
basis.	
Analyzed	different	
routes	of	
administration	
including	SQ,	IM,	
and	IV.		
	
	
	
Discussion:		
	
Ketamine	use	for	depression	is	most	often	limited	to	clinical	trials	because	it	is	not	currently	indicated	by	the	
Federal	Drug	Administration	for	depression.	It	is	not	a	standard	of	therapy	even	with	its	rapid	reduction	in	suicidal	
ideation	due	to	its	limitations.	Ketamine	is	given	in	IV	form	the	majority	of	the	time.	In	order	to	give	a	ketamine	
infusion,	the	safety	of	the	patient	must	be	monitored	which	includes	vital	sign	checks,	staffing	an	infusion	center,	
and	having	a	provider	oversee	the	process.	It	is	unknown	whether	a	psychiatrist	or	another	provider,	such	as	an	
anesthesiologist,	should	be	monitoring	the	patient	during	an	infusion.	Having	an	anesthesiologist	present	for	the	
infusion	would	be	beneficial,	in	that	they	are	familiar	with	ketamine	due	to	its	common	use	in	sedation;	however,	
they	may	not	be	well	equipped	to	handle	the	depressive	symptoms	and	any	acute	emerging	symptoms	from	the	
patient’s	mental	disorder	with	which	a	patient	may	present.		
	
Current	clinical	studies	focus	on	short-term	ketamine	use	and	the	potential	to	rapidly	reduce	symptoms	including	
suicidal	ideation.	This	is	important	for	providers	because	ketamine	may	have	a	future	potential	to	treat	a	patient	in	
an	emergent	setting	and	then	discharge	them	home	with	a	safety	plan	and	follow	up	for	further	therapy	and	
perhaps	continuing	infusions	in	an	outpatient	setting.	There	is	also	a	possibility	that	with	short-term	ketamine	use	
a	patient	may	be	able	to	re-titrate	their	antidepressants,	as	research	does	not	clearly	demonstrate	how	ketamine	
works	to	help	with	the	rapid	improvement	of	symptoms.		
	
Ketamine	may	also	have	other	novel	roles	in	the	treatment	of	mental	disorders	that	are	unexplored.	It	may	have	a	
role	as	an	adjunct	in	ECT	therapy.	Currently,	ketamine	is	not	regularly	used	as	the	sedative	in	ECT.	Most	often	
midazolam,	or	versed,	is	the	sedative	of	choice	in	ECT.	There	may	be	potential	for	ketamine	use	if	the	rapid	decline	
in	SI	will	allow	the	patient	to	return	to	normal	function	more	quickly	than	the	time	of	standard	ECT	therapy.		
	
Another	future	path	in	which	ketamine	can	be	evaluated	in	clinical	trials	is	analyzing	its	effects	over	a	greater	
period	of	time.	Currently,	the	majority	of	randomized	control	trials	are	ones	that	test	ketamine	over	a	short	period	
of	time	with	short	term	follow	up.	By	analyzing	the	long-term	use	and	effects	of	ketamine,	researchers	can	further	
test	if	the	efficacy	is	extended	for	a	greater	amount	of	time	and	if	the	side	effects	that	are	experienced	after	
infusion	persist.	Ketamine	has	a	history	of	abuse,	so	incorporating	close	short	and	long-term	follow-up	with	
patients	is	crucial	in	order	to	analyze	who	is	benefiting	from	ketamine	use	and	whether	it	should	be	more	widely	
available	as	a	treatment	for	refractory	depression.		
	
Limitations	to	ketamine	use	include	availability	and	cost.	As	mentioned	above,	Ketamine	is	often	given	in	IV	form,	
which	has	the	benefit	of	100%	bioavailability	and	is	the	most	widely	available.	Patients	with	severe	depression	may	
not	have	the	funds	or	insurance	to	cover	extensive	ketamine	infusions.	Mental	illness	treatment	can	be	a	costly	
lifetime	expense	with	hospitalizations,	medication	changes,	and	more	extensive	somatic	therapies.	Making	a	
treatment	that	is	sustainable	to	the	healthcare	system	and	to	patients	is	crucial	for	it	to	be	successful.		
	
Conclusion:		
	
Severe	refractory	depression	has	limited	treatment	options.	Ketamine	has	demonstrated	a	reduction	in	symptoms	
of	depression	and	suicidality	in	the	acute	setting	in	patients	with	treatment	resistant	depression	through	IV,	IM,	
SQ,	and	intranasal	administration.	Future	studies	should	focus	on	the	long-term	effects	of	ketamine,	continuing	to	
evaluate	the	efficacy	of	ketamine	on	symptoms	of	depression	and	suicidality,	especially	in	the	long	term,	and	the	
different	methods	of	drug	administration.	Future	ketamine	use	will	depend	on	accessibility	and	affordability	to	
patients	and	providers.		
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